• References [1,2,3,4,5,10,11,13,14]
Effect of BAS on cholesterol in clinical trials
Medication Total chol
(% decrease)
LDL
(% decrease)
Triglycerides
(% increase)
Cholestyramine (Questran®) 13 - 23% 20 - 31% 11 - 18%
Colesevelam (Welchol™) 10 - 17% 17 - 23% may increase
Colestipol (Colestid®) 7% 15 - 21% may increase
up to 21%
  • Baseline A1C was 8.2% in both trials
  • N=357 for monotherapy trial and N=159 in the metformin trial
  • In the metformin trial, colesevelam or placebo was added to metformin
  • Reference [14]
Colesevelam in placebo-controlled diabetes trials
Colesevelam 3.8 g/day monotherapy
for 24 weeks
Colesevelam 3.8 g/day + metformin
for 26 weeks
% A1C reduction
(colesevelam - placebo)
-0.27% -0.5%